Product Folix

---

name: product-folix description: Context for FoLix specifically — its target audience, key talking points, and features. Use when writing copy, landing pages, campaigns, or answering questions about FoLix. If the request involves a product but does not say which one, ASK which product before proceeding. Do NOT use for other Lumenis products; each has its own skill.

FoLix

FoLix is a hair regrowth device: a 1565 nm class 4 non-ablative fractional laser, FDA cleared for improving the appearance of scalp hair in adult males and females with Fitzpatrick skin types I–IV who are seeking treatment for hair loss.

Target audience

• Adult men and women with Fitzpatrick skin types I–IV seeking hair loss treatment, positioned for early-to-moderate stage thinning.
• Market context: 2 in 3 men face hair loss by age 35; 1 in 2 women face hair loss by age 50. (Lumenis also cites a broader stat: 85%+ of men and 50%+ of women experience hair loss, and 80M+ people affected in the US.)

Talking points

• Headline claim: first and only FDA-cleared non-ablative fractional laser for hair loss treatment. FDA cleared June 5, 2024.
• No topical anesthetic, no chemicals, no needles, no surgery, no downtime after treatment.
• Quick ~30 minute procedure.
• No consumable.
• MOA: laser promotes blood circulation and growth factors to stimulate the hair follicle.
• Awards: NewBeauty "Best Laser Treatment for Hair Loss" (2025 and 2026), MedTech Breakthrough Award 2025 (Best New Dermatology Technology Solution), Medical Device Network Excellence Award 2025 (Hair Loss Technology Innovation).

Features

• Laser specs: 1565 nm class 4 non-ablative fractional laser.
• FLX™ Technology: ensures optimal irradiance and area coverage.
• FoliCool™: patient comfort and safety.
• Clinical results: 10–18% increase in number of hairs per cm², and 13–16% additional follicular units per cm².
• Treatment protocol: recommended 3 to 6 treatments spaced 4 weeks apart; maintenance treatments recommended 2–3 times a year. (Note: most current Lumenis marketing pages instead say "4 to 6 monthly sessions" — worth confirming which protocol description is current before next use.)
• Available markets: US, Canada — Lumenis also states broader presence across the Middle East and Asia-Pacific within FoLix's first year; confirm specific countries before citing.

Competitors

• Devices: LaserMD, Alma TED.
• Orals: Nutrafol.
• Surgery: hair transplant.

How to use this

• Keep messaging consistent with the marketing positioning pillars.
• If it's unclear which product a request is about, ask first.